Neuroprogression in schizophrenia: Pathways and underpinning clinical staging and therapeutic corollaries

Australian and New Zealand Journal of Psychiatry

Volumn 49, Issue 2, 2015, Pages 183-184

  Stein, Kate ^a,b   Broome, Matthew R ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OMEGA 3 FATTY ACID; REACTIVE OXYGEN METABOLITE; TRYPTOPHAN;

COGNITIVE DEFECT; DISEASE COURSE; EPIGENETICS; HUMAN; INFLAMMATION; LETTER; PROTEIN EXPRESSION; SCHIZOPHRENIA; STAGING;

DISEASE PROGRESSION; HUMANS; SCHIZOPHRENIA;

EID: 84921329454     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867414556321     Document Type: Letter

References (5)

1. Amminger GP, Schafer MR, Papageorgiou K, et al. Long chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo-controlled trial. Archives of General Psychiatry. 2010 ; 67: 146-154
2. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and Biobehavioral Reviews. 2011 ; 35: 804-817
3. Broome MR, Woolley JB, Tabraham P, et al. What causes the onset of psychosis?. Schizophrenia Research. 2005 ; 79: 23-34
4. Davis J, Moylan S, Harvey B, et al. Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries. Australian and New Zealand Journal of Psychiatry. 2014 ; 48: 512-529
5. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophrenia Bulletin. 2009 ; 35: 549-562